About Us
Gesynta Pharma is a clinical-stage pharmaceutical company developing innovative treatments by targeting mPGES-1*, an important pro-inflammatory enzyme with a key role in endometriosis. Gesynta Pharma's research originated at Karolinska Institutet in Sweden. The company's leading compound, vipoglanstat, is a selective mPGES-1* inhibitor being developed as a new non-hormonal, non-opioid treatment with disease-modifying potential. Vipoglanstat is currently in Phase 2 clinical trials for endometriosis - a painful, chronic inflammatory disorder affecting about 10% of women of reproductive age. The condition often leads to a markedly reduced quality of life, particularly as many existing treatments fail to provide adequate symptom relief. Vipoglanstat has shown potent mPGES-1 inhibition and a favorable safety profile across Phase 1 and 2 clinical trials. Furthermore, a preclinical proof-of-concept study in an advanced model of endometriosis demonstrated that vipoglanstat significantly reduced pain-related behaviors and endometriotic lesions. A second drug candidate in the Gesynta Pharma portfolio, GS-073, is ready to enter clinical Phase 1 for the treatment of chronic inflammatory pain. The company's shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, Linc, HealthCap, XGen Venture, and other internationally renowned specialist investors. For more information, please visit www.gesynta.se. *mPGES-1: microsomal Prostaglandin E Synthase-1
Contacts
CEO
+46 (0)733 83 66 70
http://www.gesynta.se
patric.stenberg@gesynta.se
Links
Quotes
Dosing the first patient in the NOVA trial signifies a major milestone in developing vipoglanstat, aiming at providing a game-changer in the treatment of endometriosis. With a solid preclinical basis and positive clinical data on safety, tolerability, and pharmacokinetics, this trial aims to provide robust, controlled data on pain relief and quality of life for women with moderate to severe disease.
This is an important step toward expanding therapeutic options for women living with endometriosis. Despite existing treatments, many patients continue to experience persistent pain and impaired daily functioning, underscoring the need for new approaches. I am excited to work with Gesynta to assess whether vipoglanstat can deliver meaningful, lasting improvements for patients.
